Takeda appoints new head of Corporate Communications, Europe and Canada
pharmafile | July 12, 2012 | Appointment | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing | Takeda, communications
Takeda Pharmaceuticals has appointed Rob Gallo as head of Corporate Communications, Europe and Canada.
Since 2010 Gallo has been the interim head of Corporate Communications for Europe, during which time he led European-wide media campaigns for regulatory initiatives and product launches.
He also developed internal and external communication platforms during a time of organisational transformation. In his new role, which includes responsibility for Canada, Gallo will be based in Takeda’s regional head office in Zurich, Switzerland.
Prior to working at Takeda, Gallo was a director of Operandi Partners, a corporate communications and issues management consultancy based in London. At Operandi he delivered measurable improvements to corporate reputation for clients in the UK and US, and also launched an online brand reputation tracking tool in Europe.
Angie Bechan, head of Corporate Communication, CCO, at Takeda, said: “Rob has been an important member of the Takeda team for the past two years and we are delighted that he has joined us permanently. Rob brings significant experience in leading stakeholder engagement programmes and has demonstrated achievements in building communication campaigns that facilitate cultural change.”
Gallo added: “I am delighted to be joining Takeda permanently to help deliver corporate objectives in what is a very exciting stage of the company’s development.”
Related Content
Von Willebrand disease – increasing awareness and access to vital care
Pharmafile talks to Anthea Cherednichenko, Vice President Franchise Head Haematology and Transplant at Takeda about …
Combination treatments: Takeda’s Implementation Framework and the broader landscape
Pharmafile talks to Emma Roffe, Oncology Country Head (UK & Ireland) about the combination treatment …
Takeda presents positive results from trial of chronic kidney disease treatment
Takeda Pharmaceuticals has announced positive results from a proof-of-concept study of mezagitamab (TAK-079) to treat …
